Grace Therapeutics, Inc.
$2.30 -$0.03 (-1.29%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Apr 28
From its Apr 2 high, the share price fell 59%.
Peak close $5.13 on Apr 2; trough close $2.10 on Apr 28. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -59% -
Apr 23
The stock moved -45.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 23 -
Apr 6
The stock moved -20.7% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 6
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Grace Therapeutics, Inc.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.